Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Capital Expenditures (2023 - 2025)

Contineum Therapeutics has reported Capital Expenditures over the past 3 years, most recently at -$189000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at -$189000.0 for Q4 2025, up 34.83% from a year ago — trailing twelve months through Sep 2025 was -$101000.0 (down 115.37% YoY), and the annual figure for FY2024 was $58000.0, down 85.99%.
  • Capital Expenditures for Q4 2025 was -$189000.0 at Contineum Therapeutics, down from $98000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for CTNM hit a ceiling of $309000.0 in Q4 2023 and a floor of -$290000.0 in Q4 2024.
  • Median Capital Expenditures over the past 3 years was $49500.0 (2023), compared with a mean of $39333.3.
  • Peak annual rise in Capital Expenditures hit 283.87% in 2024, while the deepest fall reached 193.85% in 2024.
  • Contineum Therapeutics' Capital Expenditures stood at $309000.0 in 2023, then plummeted by 193.85% to -$290000.0 in 2024, then soared by 34.83% to -$189000.0 in 2025.
  • The last three reported values for Capital Expenditures were -$189000.0 (Q4 2025), $98000.0 (Q3 2025), and $44000.0 (Q2 2025) per Business Quant data.